Primary sclerosing cholangitis (PSC) patients are at risk of developing cholangiocarcinoma (CCA). We have shown that (1) histamine increases biliary hyperplasia through H1/H2 histamine receptors (HRs) and (2) histamine levels increase and mast cells (MCs) infiltrate during PSC and CCA. We examined the effects of chronic treatment with H1/H2HR antagonists on PSC and CCA. Wild-type and multidrug-resistant knockout (Mdr2 -/-) mice were treated by osmotic minipumps with saline, mepyramine, or ranitidine (10 mg/kg body weight/day) or a combination of mepyramine/ranitidine for 4 weeks. Liver damage was assessed by hematoxylin and eosin. We evaluated (1) H1/H2HR expression, (2) MC presence, (3) L-histidine decarboxylase/histamine axis, (4) cholangiocyte proliferation/bile duct mass, and (5) fibrosis/hepatic stellate cell activation. Nu/nu mice were implanted with Mz-ChA-1 cells into the hind flanks and treated with saline, mepyramine, or ranitidine. Tumor growth was measured, and (1) H1/H2HR expression, (2) proliferation, (3) MC activation, (4) angiogenesis, and (5) epithelial-mesenchymal transition (EMT) were evaluated. In vitro, human hepatic stellate cells were evaluated for H1HR and H2HR expression. Cultured cholangiocytes and CCA lines were treated with saline, mepyramine, or ranitidine (25 lM) before evaluating proliferation, angiogenesis, EMT, and potential signaling mechanisms. H1/H2HR and MC presence increased in human PSC and CCA. In H1/H2HR antagonist (alone or in combination)-treated Mdr2 -/-mice, liver and biliary damage and fibrosis decreased compared to saline treatment. H1/H2HR antagonists decreased tumor growth, serum histamine, angiogenesis, and EMT. In vitro, H1/H2HR blockers reduced biliary proliferation, and CCA cells had decreased proliferation, angiogenesis, EMT, and migration. Conclusion: Inhibition of H1/H2HR reverses PSC-associated damage and decreases CCA growth, angiogenesis, and EMT; because PSC patients are at risk of developing CCA, using HR blockers may be therapeutic for these diseases. (HEPATOLOGY 2018; 68:1042-1056.
Primary sclerosing cholangitis (PSC) patients are at risk of developing cholangiocarcinoma (CCA). We have shown that (1) histamine increases biliary hyperplasia through H1/H2 histamine receptors (HRs) and (2) histamine levels increase and mast cells (MCs) infiltrate during PSC and CCA. We examined the effects of chronic treatment with H1/H2HR antagonists on PSC and CCA. Wild-type and multidrug-resistant knockout (Mdr2 -/-) mice were treated by osmotic minipumps with saline, mepyramine, or ranitidine (10 mg/kg body weight/day) or a combination of mepyramine/ranitidine for 4 weeks. Liver damage was assessed by hematoxylin and eosin. We evaluated (1) H1/H2HR expression, (2) MC presence, (3) L-histidine decarboxylase/histamine axis, (4) cholangiocyte proliferation/bile duct mass, and (5) fibrosis/hepatic stellate cell activation. Nu/nu mice were implanted with Mz-ChA-1 cells into the hind flanks and treated with saline, mepyramine, or ranitidine. Tumor growth was measured, and (1) H1/H2HR expression, (2) proliferation, (3) MC activation, (4) angiogenesis, and (5) epithelial-mesenchymal transition (EMT) were evaluated. In vitro, human hepatic stellate cells were evaluated for H1HR and H2HR expression. Cultured cholangiocytes and CCA lines were treated with saline, mepyramine, or ranitidine (25 lM) before evaluating proliferation, angiogenesis, EMT, and potential signaling mechanisms. H1/H2HR and MC presence increased in human PSC and CCA. In H1/H2HR antagonist (alone or in combination)-treated Mdr2 -/-mice, liver and biliary damage and fibrosis decreased compared to saline treatment. H1/H2HR antagonists decreased tumor growth, serum histamine, angiogenesis, and EMT. In vitro, H1/H2HR blockers reduced biliary proliferation, and CCA cells had decreased proliferation, angiogenesis, EMT, and migration. Conclusion: Inhibition of H1/H2HR reverses PSC-associated damage and decreases CCA growth, angiogenesis, and EMT; because PSC patients are at risk of developing CCA, using HR blockers may be therapeutic for these diseases. (HEPATOLOGY 2018; 68:1042-1056).
P rimary sclerosing cholangitis (PSC) is a chronic inflammatory condition that affects both intrahepatic and extrahepatic cholangiocytes. (1, 2) In conditions of chronic cholestasis, cholangiocytes proliferate and secrete neuroendocrine factors, (3) (4) (5) inducing fibrosis through hepatic stellate cell (HSC) activation. (6, 7) PSC is characterized by inflammation and is a prominent risk factor for developing cholangiocarcinoma (CCA), (1, 8) a devastating liver cancer that has a difficult diagnosis coupled with a significant lack of beneficial therapeutics. (1) The risk of developing CCA increases dramatically in patients previously diagnosed with PSC, (9) and the link between the two has been attributed to advanced age at diagnosis, smoking, alcohol consumption, genetic alterations, and other environmental factors. (8, 9) Studies to examine the progression of PSC and CCA include the multidrug resistance gene knockout (Mdr2 -/-) mouse model of PSC (7, 10, 11) and xenograft models of CCA using immunocompromised mice, (12, 13) respectively. Mdr2 -/-mice develop a human-like phenotype of PSC as they age, beginning around 4 weeks of age when there is distinct biliary hyperplasia and inflammation. (7, 10) Fibrosis in Mdr2 -/-mice is present beginning at 4 weeks of age and progresses beyond 12 weeks of age. Interestingly, Mdr2
-/-mice develop hepatocellular carcinoma as they reach 1 year of age. (14) The xenograft model of CCA is used to examine tumor progression, angiogenesis, and epithelial-to-mesenchymal transition (EMT). (12, 13) Histamine interacts with one of four G protein-coupled histamine receptors (HRs) to promote liver damage and hepatic fibrosis in human PSC, Mdr2
-/-mice, and xenograft models of CCA. (7, 12, 15, 16) This inflammatory mediator is secreted by cholangiocytes and regulates autocrine signaling in the biliary tree (15) but is also abundantly secreted by degranulating mast cells (MCs), (17) demonstrating a paracrine role for MCs during liver damage. We have shown that MCs migrate close to bile ducts within the liver following damage including cholestatic injury, PSC progression, and CCA development. (5) (6) (7) 12) Further, blocking MC activation using cromolyn sodium decreases biliary damage, hepatic fibrosis, and CCA growth. (7, 12) Also, MC-deficient mice subjected to bile duct ligation had significantly less damage and fibrosis than wild-type (WT) mice, and injection of cultured MCs into MCdeficient mice increased damage and hepatic fibrosis, pinpointing MCs as critical regulators of liver disease. (6) Chronic usage of HR blockers has significantly increased in the past decade. Patients suffering from allergies, asthma, gastric acid secretion, and reflux are consuming large quantities of H1HR and H2HR antagonists like Allegra, Zantac, Prilosec, and Zyrtec. H1HR and H2HR are stimulatory receptors that induce a number of biological effects including cellular proliferation. (16) Further, H1HR increases small, but not large, biliary mass, whereas H2HR agonist treatment increases only large biliary mass. (16) We postulate that chronic usage of these drugs may ameliorate PSC-induced hepatic damage and fibrosis as well as reducing CCA tumor growth, angiogenesis, and metastasis.
Materials and Methods

ANIMAL MODELS
PSC Mouse Model
Male WT and Mdr2 -/-mice (8 weeks of age) were implanted with osmotic minipumps to deliver 0.9% NaCl (saline) or 10 mg/kg body weight (BW)/ day (18, 19) of either mepyramine (H1HR antagonist) or ranitidine (H2HR antagonist). In separate experiments, male Mdr2 -/-mice (8 weeks of age) were treated with a combination of mepyramine and ranitidine (H1HR/H2HR antagonist) for 4 weeks to mimic chronic usage. Male mice (8-10 mice per group) were euthanized at 12 weeks of age, when these mice display an increase in PSC-induced hepatic damage. (7, 10) From these groups, we collected liver blocks (frozen and paraffin-embedded), serum, cholangiocytes, and cholangiocyte supernatants, as described. (7, 20) 
CCA Mouse Model
For xenograft experiments, male nu/nu mice were implanted with Mz-ChA-1 cells (3 3 10 6 cells per injection) into both hind flanks, allowing for tumor development, according to our previous studies. (13, 15, 21) After 10 days of implantation, tumor formation and establishment occurred. Following tumor formation, mice were treated with saline (NaCl), mepyramine, or ranitidine (10 mg/kg BW/day) (6 mice per group 5 12 tumors per group) by intraperitoneal injection 3 times per week for 31 days, along with tumor measurement: mm 3 
. (13, 15, 21) Then, we collected serum, tissue, and excised tumors for frozen and paraffin-embedded processing, as described by us. (12) 
HUMAN SAMPLES AND TISSUE ARRAYS
Human liver sections from control (obtained from areas of nondiseased livers taken during resection following CCA diagnosis), PSC patients, and CCA tissues were used. PSC patients presented with a range of early-stage to late-stage PSC, as described in our previous work. (7) Liver sections (4-5 lm thick) were obtained by needle biopsies from 3 control patients, 3 PSC patients, and 6 CCA patients. Serum samples were obtained from 3 control patients and 3 CCA patients, which were separate from the above patient samples. Deidentified samples were provided by Dr. Pietro Invernizzi (Humanitas Research Hospital, Rozzano, Italy) under a protocol approved by the Ethics Committee of the Humanitas Research Hospital; the protocol was approved by the Central Texas Veterans Health Care System Institutional Review Board and Research and Development Committee. Human CCA tissue arrays, used as described by us, (13, 15, 21) were obtained from Pantomics (Richmond, CA). -/-mice, and human PSC and CCA. (15) Also, L-histidine decarboxylase (HDC) expression was evaluated by real-time PCR in all groups following treatment with vehicle or H1HR or H2HR antagonist. Histamine secretion was evaluated by enzyme immunoassay in serum from all groups of mice and in human serum from controls or patients with CCA. (6, 7, 12) MC presence was measured by immunohistochemistry for mouse MC protease-1 (mMCP-1) in Mdr2 -/-mice treated with saline or H1HR or H2HR antagonist and toluidine blue staining in tumors from treated nu/nu mice. mRNA expression of c-Kit, chymase, and tryptase was measured in livers and tumors from all groups of mice. Real-time PCR was performed using delta delta cycle threshold. (6, 7, 12) MEASUREMENT -/-mice treated with H1HR or H2HR blocker or combined H1HR/H2HR blockers were evaluated for liver fibrosis by staining for Masson's trichrome and fast green/sirius red and by real-time PCR for fibronectin-1 and collagen type 1a. (6, 7) To determine if H1HR or H2HR inhibition (or a combination of both) alters HSC activation, we measured the expression of synaptophysin-9 (SYP-9) by immunofluorescence and real-time PCR. (6, 7) ASSESSMENT OF TUMOR GROWTH AND CHOLANGIOCYTE PROLIFERATION IN CCA Nu/nu mice were evaluated for tumor growth and proliferation. Tumor measurements were taken 3 times a week using an electronic caliper in nu/nu mice. Volume of tumor mass was calculated as described by us. (12, 13, 15) In excised tumors, proliferating cellular nuclear antigen (PCNA) gene expression was measured by real-time PCR and immunohistochemistry was performed for Ki-67 to detect cholangiocyte proliferation.
MORPHOLOGICAL ANALYSIS OF
EVALUATION OF ANGIOGENESIS, VASCULAR ALTERATIONS, AND EMT IN CCA
In excised tumors from nu/nu mice treated with saline, H1HR blocker, or H2HR blocker and in human samples from controls or CCA patients, we evaluated angiogenesis and vascular cell activity by real-time PCR for vascular endothelial growth factor A (VEGF-A) and immunohistochemistry and immunofluorescence for von Willebrand factor (vWF), respectively. (6) EMT was evaluated by immunohistochemistry for CK-7, vimentin, and E-cadherin in tumors from nu/nu treated mice (saline, H1HR or H2HR antagonist) and human samples from controls or CCA patients. (13) 
IN VITRO STUDIES
To determine which specific cell type is involved in the action mediated by H1HR or H2HR, we performed in vitro studies in normal mouse cholangiocytes (Pool MSE chol), immortalized small mouse cholangiocytes (Small MSE chol), immortalized large mouse cholangiocytes (Large MSE chol), human CCA (Mz-ChA-1) cells, human HSCs (hHSCs), and cultured MCs (MC/9; ATCC CRL-8306). All cells were maintained and cultured as described. (15, 16, 22) Cells were treated with vehicle (0.1% bovine serum albumin), mepyramine (25 lM), or ranitidine (25 lM) for 6-72 hours for specific experiments outlined below.
DETERMINATION OF CHOLANGIOCYTE PROLIFERATION AND EVALUATION OF CCA PROLIFERATION, ANGIOGENESIS, AND EMT FOLLOWING TREATMENT WITH H1HR OR H2HR INHIBITOR, IN VITRO
Cholangiocytes were treated with H1HR or H2HR antagonist, and proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTS) assay and bromodeoxyuridine (BrdU) incorporation. (15, 16, 22) Similar to our in vivo studies, we performed experiments to determine the effects of blocking either H1HR or H2HR on CCA proliferation by an MTS assay and angiogenesis and EMT by real-time PCR. CCA cells were treated for up to 24 hours with vehicle, mepyramine, or ranitidine prior to MTS assay and real-time PCR. Invasion was measured using a commercially available kit following vehicle, H1HR antagonist, or H2HR antagonist treatment. The QCM ECMatrix Cell Invasion Assay was purchased from EMD Millipore (Billerica, MA) and used per the manufacturer's instructions. (13) 
DETECTION OF H1HR AND H2HR EXPRESSION IN hHSCs AND ASSESSMENT OF hHSC ACTIVATION FOLLOWING TREATMENT WITH H1HR OR H2HR INHIBITOR, IN VITRO
To determine if hHSCs express H1HR or H2HR, we performed reverse-transcription PCR and real-time PCR and compared expression levels to cultured MCs and cholangiocytes, which express H1HR and H2HR. (16) To evaluate whether H1HR or H2HR antagonism mediates hHSC activation, we took hHSCs treated with vehicle, mepyramine, or ranitidine and measured the mRNA levels of collagen type 1a by real-time PCR.
EVALUATION OF THE SYNERGISTIC EFFECTS BETWEEN MCs, CHOLANGIOCYTES, AND CCA CELLS
Because MCs infiltrate during PSC, increasing fibrosis, and are up-regulated during CCA, we evaluated the synergistic effects of MCs treated with H1HR or H2HR blocker on cholangiocytes and CCA cells. MCs were treated with vehicle, mepyramine, or ranitidine; and supernatants were collected and stored at -808C.
In our first experiments, cholangiocytes were treated with collected MC supernatants and proliferation was measured by MTS assay and BrdU incorporation. Next, CCA cells were treated with MC supernatants collected following treatment with vehicle, mepyramine, or ranitidine; and we evaluated proliferation, angiogenesis, and EMT as detailed above.
DETERMINATION OF THE SIGNALING PATHWAYS MEDIATING SMALL AND LARGE CHOLANGIOCYTES AND CCA FUNCTION
In vitro, Small MSE chol and Large MSE chol were treated with vehicle, histamine (10 lM), forskolin (25 lM), mepyramine, or ranitidine prior to evaluating inositol trisphosphate (IP 3 ) and cAMP levels using the IP 3 kit from CisBio US, Inc. (Bedford, MA) and the Cyclic AMP ELISA Kit (Cayman Chemical, Ann Arbor, MI), respectively. In tumors from nu/nu mice treated with vehicle or H1HR and H2HR antagonist, we evaluated the Notch/Jagged signaling pathway by immunohistochemistry.
STATISTICAL METHODS
All data are expressed as mean 6 SEM. Groups were analyzed by the Student unpaired t test for two groups or a two-way analysis of variance for more than two groups, followed by an appropriate post hoc test. P < 0.05 was considered significant.
Results
CHRONIC TREATMENT WITH H1HR OR H2HR BLOCKER AMELIORATES HEPATIC DAMAGE IN Mdr2 -/-MICE BUT HAS NO DETRIMENTAL EFFECT IN WT MICE
By hematoxylin and eosin we found that long-term usage of H1HR or H2HR antagonist had no negative effects on WT mice. However, in Mdr2 -/-mice treated with either the H1HR antagonist, H2HR antagonist, or H1HR/H2HR antagonist combination, the degree of lobular damage, necrosis, and inflammation was reduced compared to Mdr2 -/-mice treated with saline (Supporting Fig. S1 ).
H1 AND H2 HR EXPRESSION IS INCREASED IN PSC AND CCA
By immunohistochemistry, we found that, in WT mice, H1HR expression was absent in both small and large cholangiocytes; however, following injury (Mdr2 -/-mice), H1HR expression was increased in both small and large cholangiocytes, with a more profound increase in small cholangiocytes (Fig. 1A) . H2HR expression was absent in small cholangiocytes and slightly present in large cholangiocytes in WT mice; however, Mdr2 -/-mice showed a significant increase in H2HR expression in large cholangiocytes but not small cholangiocytes (Fig. 1A) . Additionally, we found that the expression of H1HR and H2HR is up-regulated in human PSC ( 
MC ACTIVATION AND THE HDC/ HISTAMINE AXIS ARE REDUCED IN Mdr2 -/-MICE TREATED WITH H1HR OR H2HR INHIBITOR
We found that MC activation is decreased in Mdr2 -/-mice (shown by mMCP-1 staining) and nu/ nu mice (shown by toluidine blue staining) treated with H1HR or H2HR antagonist ( Fig. 2A,B) . Further, MC markers were significantly decreased in Mdr2 -/-mice and tumors from nu/nu mice treated with either H1HR or H2HR antagonist (Fig. 2C,D) .
HDC expression was increased in Mdr2 -/-mice, nu/nu mice, and human PSC and CCA (Fig. 3A-C) ; however, when Mdr2 -/-mice or nu/nu mice were treated with H1HR or H2HR antagonist the expression of HDC significantly decreased (Fig. 3A,B) . We previously demonstrated that histamine levels increase in PSC, (7) and here we found that histamine serum levels were decreased in both Mdr2 -/-mice ( Fig. 3D ) and nu/nu mice (Fig. 3E ) treated with either H1HR or H2HR blocker compared to saline treatment.
Further, histamine serum levels also increased in patients with CCA compared to controls (Fig. 3F) .
BILIARY PROLIFERATION AND IBDM ARE SIGNIFICANTLY REDUCED FOLLOWING TREATMENT WITH EITHER H1HR OR H2HR BLOCKER
We found that long-term usage of H1HR or H2HR antagonist had no effect on IBDM or biliary proliferation in WT mice (Fig. 4A,B) . Biliary proliferation and IBDM were significantly down-regulated in
FIG. 1. Expression of H1HR and H2HR in Mdr2
-/-mice, nu/nu mice, and human PSC and CCA. Immunohistochemistry for H1HR and H2HR was performed in liver sections from WT, Mdr2 -/-mice, nu/nu mice, human control, and human PSC. H1HR expression was found in both small and large ducts of Mdr2 -/-mice (but not in WT mice), with a more pronounced expression in small ducts (A). In WT mice, H2HR expression was low in large bile ducts but absent in small bile ducts; however, in Mdr2 -/-mice, H2HR expression was increased in large bile ducts but not small (A). Both H1 and H2 HRs are expressed at low levels in human control liver sections, but the expression of H1 and H2 HRs is increased in human PSC compared to controls (B). Tumors from nu/ nu mice treated with saline expressed increased levels of H1HR and H2HR, particularly in CCA cells versus stromal cells (C). Both H1 and H2 HRs are expressed at low levels in human nonmalignant liver sections, but expression of both of these receptors is increased in human CCA when compared to nonmalignant controls (D). Representative images are 320 magnification.
Mdr2
-/-mice following chronic exposure to either H1HR or H2HR inhibitor or the H1HR/H2HR antagonist combination (Fig. 4A,B) . Treatment with H1HR reduced small cholangiocyte proliferation, whereas H2HR inhibition reduced large cholangiocyte proliferation, demonstrating that these receptors have differential action during biliary damage (Supporting Fig. S2 ). Combination treatment with both the H1HR and H2HR antagonists decreased both small and large cholangiocyte proliferation in Mdr2 -/-mice when compared to saline-treated mice (Supporting Fig. S2 ).
Mdr2 -/--ASSOCIATED FIBROSIS, COLLAGEN DEPOSITION, AND HSC ACTIVATION DECREASE FOLLOWING INHIBITION OF H1HR OR H2HR
Fast green/sirius red staining and semiquantification ( Fig. 5A; Supporting Fig. S3A ) as well as Masson's trichrome (Fig. 5B ) reveal a decrease in collagen deposition in Mdr2 -/-mice treated with H1HR or H2HR antagonist or the combination of the two when
FIG. 2. MC expression in Mdr2
-/-mice and nu/nu mice. MCs were detected by mMCP-1 immunohistochemistry in Mdr2 -/-1 saline and Mdr2 -/-mice treated with either H1HR or H2HR antagonist (A). Mdr2 -/-mice treated with saline displayed numerous MCs surrounding bile ducts (as shown by red arrows), whereas the inhibition of either H1HR or H2HR by antagonist treatment ablated the infiltration of MCs when compared to Mdr2 -/-1 saline (A). Toluidine blue staining was performed in tumors from nu/ nu mice treated with saline or H1HR or H2HR antagonist to detect MC number (B). In nu/nu mice treated with saline there were numerous infiltrating MCs (as shown by red arrows), and treatment with either an H1HR or H2HR antagonist decreased MC number when compared to nu/nu 1 saline (B). MC activation was detected by quantitative PCR for c-Kit, chymase, and tryptase in total liver from WT, Mdr2 -/-1 saline, and Mdr2 -/-mice treated with H1HR or H2HR antagonist (C) and in tumors from nu/nu mice treated similarly (D). The expression of MC markers was significantly increased in Mdr2 -/-1 saline mice when compared to WT, but the expression of these markers was decreased in Mdr2 -/-mice treated with either H1HR or H2HR antagonist when compared to saline-treated mice (C). Expression of chymase was not significantly decreased in nu/nu mice treated with the H1HR or the H2HR antagonist; however, tryptase levels were significantly decreased in nu/nu mice treated with either antagonist when compared to saline-treated mice (D). Data are mean 6 SEM of nine experiments for real-time PCR. *P < 0.05 versus WT, # P < 0.05 versus Mdr2 -/-saline treatment. Representative images are 320 magnification.
compared to saline-treated mice. WT mice treated with either H1HR or H2HR blocker had no visible change in collagen deposition (Fig. 5A) . The expression of fibronectin and collagen type-1a is significantly reduced in Mdr2 -/-mice treated with either H1HR or H2HR antagonist or the H1HR/H2HR combination when compared to saline (Supporting Fig. S3B,C) . HSC activation was decreased in Mdr2 -/-mice treated with either H1HR or H2HR antagonist or the H1HR/H2HR combination when compared to saline-treated mice as shown by immunofluorescence for SYP-9 ( Fig. 5C ) and real-time PCR (Supporting Fig. S3D ).
TREATMENT WITH H1HR OR H2HR ANTAGONIST DID NOT AFFECT HSC ACTIVATION, IN VITRO
We found that hHSCs express H1HR but have minimal expression of H2HR when compared to cultured MCs and cholangiocytes (Supporting Fig. S4A,  B) . However, when hHSCs were treated with either the H1HR or H2HR antagonist there was no change in collagen type 1a expression (Supporting Fig. S4C ), indicating that HR antagonism does not directly affect HSC activation. We conclude that H1HR or H2HR
FIG. 3. Evaluation of the HDC/histamine axis in Mdr2
-/-mice, nu/nu mice, and human PSC and CCA. Hepatic expression of HDC is increased in Mdr2 -/-mice treated with saline when compared to WT, but expression is decreased in mice treated with either H1HR or H2HR antagonist when compared to saline-treated mice (A). HDC expression is decreased in tumors from nu/nu mice treated with the H1HR or the H2HR antagonist when compared to saline-treated mice (B). Hepatic HDC expression increased in human PSC and CCA compared to controls (C). Histamine secretion increased in serum from Mdr2 -/-saline-treated mice compared to WT, but histamine secretion was reduced in Mdr2 -/-mice treated with the H1HR or H2HR antagonist when compared to salinetreated mice (D). Serum histamine levels were decreased in nu/nu mice treated the H1HR and H2HR antagonist when compared to saline-treated mice (E). Histamine secretion increased in human CCA compared to nonmalignant controls (F). Data are mean 6 SEM of 12 experiments for real-time PCR and at least 10 experiments for enzyme immunoassay. *P < 0.05 versus WT, control, or nonmalignant; # P < 0.05 versus Mdr2 -/-saline treatment.
antagonism directly modulates biliary proliferation and activation, which in turn mediates HSC activation and subsequent liver fibrosis.
TREATMENT WITH H1HR OR H2HR ANTAGONIST DECREASES TUMOR GROWTH IN nu/nu MICE
Tumor volume significantly increased over time when nu/nu mice were treated with saline, whereas treatment with either H1HR or H2HR blunted tumor growth beginning at day 13 and continuing throughout the treatment (Fig. 6A) . In tumors from nu/nu mice treated with saline, PCNA expression was significantly up-regulated; but it was reduced in nu/nu mice following treatment with either H1HR or H2HR antagonist (Fig. 6B) , and Ki-67-positive cholangiocytes were reduced following treatment with either H1HR or H2HR antagonist (Fig. 6C ).
H1HR AND H2HR INHIBITION DECREASES ANGIOGENESIS AND REVERSES EMT IN HUMAN CCA
In nu/nu mice treated with saline, the expression of vWF was increased; however, treatment with H1HR or H2HR blocker decreased vWF expression in nu/nu mice tumors (Fig. 7A) . VEGF-A expression increased in nu/nu mice treated with saline but was significantly reduced in mice treated with either H1HR or H2HR
FIG. 4. Measurement of biliary proliferation and IBDM in Mdr2
-/-mice. Biliary proliferation is unchanged in WT mice treated with either H1HR or H2HR antagonist when compared to saline-treated WT mice (A). However, biliary proliferation is increased in Mdr2 -/-mice treated with saline when compared to WT but reduced in Mdr2 -/-mice following chronic treatment with either H1HR or H2HR antagonist when compared to saline-treated mice (A). Similarly, IBDM was unchanged in WT mice treated with H1HR, H2HR, or H1HR/H2HR antagonist when compared to saline-treated WT mice (A). IBDM increased in Mdr2 -/-mice treated with saline when compared to WT mice but significantly decreased in Mdr2 -/-mice following administration of H1HR, H2HR, or H1HR/ H2HR antagonist when compared to saline treatment (B). Data are mean 6 SEM of 12 cumulative experiments from 6-8 mice per group. *P < 0.05 versus WT, # P < 0.05 versus Mdr2 -/-saline treatment. Representative images are 320 magnification.
antagonist (Fig. 7B) . With regard to EMT, in nu/nu mice, CK-7 and E-cadherin were up-regulated in tumors from nu/nu mice treated with H1HR or H2HR antagonist compared to tumors from mice treated with saline, while the expression of vimentin was dramatically reduced, demonstrating a shift in and reversal of EMT progression during CCA following H1HR or H2HR inhibition (Fig. 7C) . To verify our findings in human CCA, we found that the expression of vWF was increased in human CCA (Supporting Fig. S5 ) and, with respect to EMT, the epithelial markers CK-7 and E-cadherin were increased in human CCA along with vimentin (mesenchymal marker) expression, demonstrating that these cells are vascular and potentially entering EMT switch (Supporting Fig. S5 ).
TREATMENT WITH H1HR OR H2HR ANTAGONIST DECREASES CHOLANGIOCYTE AND CCA PROLIFERATION AND CCA INVASION, ANGIOGENESIS, AND EMT, IN VITRO
Cholangiocyte proliferation is reduced following treatment with either H1HR or H2HR antagonist compared to vehicle treatment (Supporting Fig. S6 ).
FIG. 5. Assessment of hepatic fibrosis in WT and Mdr2
-/-mice. In Mdr2 -/-mice treated with saline there was increased collagen content and bridging fibrosis (as shown by sirius red and Masson trichrome staining) when compared to WT mice; however, this was ameliorated in Mdr2 -/-mice treated with either H1HR or H2HR antagonist when compared to saline-treated mice (A,B). WT mice treated with H1HR or H2HR antagonist displayed little to no collagen deposition as shown by sirius red (A). HSC activation was measured by SYP-9 (green) immunofluorescence costained with CK-19 (red) to image bile ducts (C). There was an increase in activated HSCs in Mdr2 -/-mice treated with saline when compared to WT mice, which was ablated in Mdr2 -/-mice treated with either H1HR or H2HR antagonist when compared to saline-treated mice (C). Representative images are 320 for colorimetric staining and 320 for immunofluorescence. Abbreviation: DAPI, 4',6-diamidino-2-phenylindole.
Similarly, CCA proliferation, invasion, and vWF expression decreased after treatment with either H1HR or H2HR antagonist (Supporting Fig. S7A-C) . The expression of E-cadherin increased in CCA cells treated with either H1HR or H2HR antagonist compared to vehicle (Supporting Fig. S7D ).
SYNERGISTIC EFFECTS OF MCs, CHOLANGIOCYTES, AND CCA, IN VITRO
MCs were pretreated with either 0.1% bovine serum albumin (vehicle) or the H1HR or H2HR antagonist, and supernatants were collected (Supporting Fig.  S8A) . MC supernatants were then used to stimulate either cholangiocytes or Mz-ChA-1 cells for up to 72 hours (Supporting Fig. S8 ). Coculture experiments revealed that when MCs were pretreated with 0.1% bovine serum albumin (basal), cholangiocyte and CCA proliferation increased; however, both cholangiocyte and CCA proliferation decreased following treatment with MCs plus H1HR or H2HR antagonist as shown by BrdU incorporation and MTS assay (Supporting Fig. S8A-C) .
Similar to our previous work, inhibition of H1HR decreased histamine-stimulated IP 3 levels in small cholangiocytes (Supporting Fig. S9A ) but did not alter large cholangiocyte IP 3 levels (not shown). When large cholangiocytes were treated with forskolin (which increases cAMP levels (23) ) intracellular cAMP levels dramatically increased, though this was blocked by treatment with the H2HR antagonist (Supporting Fig. S9B ). Inhibition of H2HR had no significant effect on small cholangiocyte intracellular cAMP levels (not shown). In nu/nu mice, treatment with NaCl increased Notch 1/2 and Jagged 1 as shown by FIG. 6 . Tumor growth and proliferation evaluation in nu/nu mice. Tumor growth was measured in nu/nu mice treated with NaCl, the H1HR, or the H2HR antagonist following tumor establishment (A). Tumors were measured every other day for 31 days. Growth of tumors significantly increased in nu/nu mice treated with saline beginning at day 13 and continued throughout the experiment (A). Nu/nu mice treated with either H1HR or H2HR antagonist had blunted tumor growth throughout the treatments compared to NaCl-treated mice (A). PCNA gene expression decreased in tumors from nu/nu mice treated with either H1HR or H2HR antagonist compared to saline treatment (B), and Ki-67 staining was reduced in tumors from nu/nu mice treated with H1HR or H2HR antagonist compared to saline treatment (C). Data are mean 6 SEM of six experiments for real-time PCR. *P < 0.05 versus saline treatment. Representative images are 320 magnification.
immunohistochemistry (Supporting Fig. S10 ), and treatment with either the H1HR or the H2HR antagonist decreased the expression of these factors (Supporting Fig. S10 ).
Discussion
Our study demonstrates a use for readily available drugs that inhibit histamine receptors, which may be therapeutically beneficial to ameliorate both PSC and CCA progression. Treatment with H1HR or H2HR inhibitor and the combined H1HR/H2HR antagonist successfully reversed liver damage, biliary ductular reaction, liver fibrosis, and inflammation in Mdr2 -/-mice; and no detrimental effects were found in WT mice. In addition, mice implanted with xenograft tumors and treated with either H1HR or H2HR antagonist displayed blunted tumor growth, decreased vascular angiogenesis, and a reversal of EMT. Our findings show that inhibition of histamine signaling by receptor antagonism alleviates features of both PSC and CCA.
Numerous studies provide a link between PSC and CCA, and it is well known that patients with PSC have an increased risk of developing CCA, especially if the PSC is diagnosed late or they are not responsive to therapy. (9, 24, 25) Further, large-duct PSC more commonly develops into a malignant state versus smallduct PSC. (25) In support of this, we found that both small and large IBDM and cholangiocyte proliferation increased in Mdr2 -/-mice; however, the increase in large was higher than that in small IBDM, suggesting that there is a critical role for large bile ducts during PSC damage. Further, we found that large IBDM was significantly increased in Mdr2 -/-mice and that treatment with the H2HR antagonist decreased large IBDM, whereas the H1HR blocker targeted small cholangiocyte proliferation. Combination treatment inhibited both small and large biliary proliferation and ductal mass. This is supportive of our previous work demonstrating that these receptors have specific targets in the biliary tree, (16) and further investigation of their effects is warranted.
Recently, it has been reported that PSC patients have a 5%-20% greater lifetime risk of developing CCA versus other chronic liver disease populations. (24) Additionally, it has been demonstrated that the overall risk for CCA increases over 160-fold when comparing PSC patients to the general population. (26) Besides CCA, PSC patients are at a greater risk of developing gallbladder cancer, pancreatic cancer, and colorectal malignancies. (24) Our work supports the hypothesis that enhanced histamine levels or MC markers may be potential biomarkers for early detection of both PSC and CCA.
The histamine/HR axis is a critical regulator of biliary damage and repair. (13, 15, 16, 21) Treatment with H1HR or H2HR agonist increases biliary proliferation and induces proliferation in normal rats, and when immunocompromised mice were implanted with xenograft tumors and treated with histamine, tumor growth significantly increased. (15, 16) Our previous work shows that inhibition of HDC using a-methyl-dl-histidine decreases bile duct ligation-induced damage and CCA progression. (15, 22) We found that stimulation of H3HR decreased bile duct ligation-related proliferation and CCA growth, (21) and in a separate study we found that usage of the H4HR agonist clobenpropit significantly blunted tumor growth and reversed EMT associated with CCA. (13) Thus, histamine is a potent trophic agent that induces biliary damage, tumor growth, and hepatic fibrosis through HR interaction. Specifically, we note that the fibrotic effects of histamine are mediated through biliary proliferation and activation, which in turn modulates HSC activation and fibrogenesis. Thus, we propose that histamine indirectly affects HSC activation, even though HSCs express both H1HR and H2HR.
For our studies we used a dose of 10 mg/kg BW (18, 19) for both H1HR and H2HR antagonists (and in our combination treatment) and delivered drugs every day for 4 weeks to recapitulate chronic usage. Human dosing for different H1HR and H2HR blockers ranges from 10 mg/day to 180 mg/day. For example, the standard dosing for ranitidine in humans is 300 mg/day divided into two doses, but the maximum dose listed is as much as 6 g/day (www. epocrates.com). Ranitidine dosing for children is typically between 4 and 10 mg/kg BW/day (www.pdr.net). Our dose is well within the maximum dose of 85.7 mg/kg BW/day. Most importantly, at this dosage we were able to significantly reverse many of the damaging features of both PSC and CCA including fibrosis and tumor growth. In our current study, treatment with H1HR or H2HR blocker reduced MC activation along with decreasing histamine levels, thereby ameliorating PSC-induced or CCA-induced damage. In relation to PSC, which is characterized by increased fibrosis and collagen deposition, it has been shown that MCs induce fibroblast proliferation and collagen synthesis, (27) supporting our current study. MCs play a detrimental role in tumor formation, growth, and metastasis during pancreatic cancer, colorectal cancer, and gastric cancer, to name a few. (28) (29) (30) Extensive studies have found that hepatocellular cancer and CCA can be driven by increased histamine levels and MC activation. (27, 31) Our study reveals that inhibition of HRs decreases MC activation, leading to decreased tumor growth and angiogenesis along with a reversal of EMT. In endothelial cells, MC inhibition using cromolyn sodium improved the efficacy of antiangiogenic therapy, suggesting a mechanism of combining MC inhibitors and anti-growth factor inhibitors to decrease tumor burden. (32) We also found an up-regulation of both H1HR and H2HR in tumors of Mdr2 -/-mice and nu/nu mice as well as in human PSC and CCA. In support of this, the expression of both HRs has been found to be upregulated in intestinal tissue samples from irritable bowel syndrome (IBS) patients, a syndrome from which 70% of PSC patients suffer. (33) Further, increased H1HR activation induces an increase in inflammation, whereas H2HR was found to decrease inflammation. (33) Patients using ketotifen to block H1HR received relief from IBS symptoms including a reduction in abdominal pain; however, it was not clear if this drug also blocked MC activation. (34) A separate study found that using ebastine, a second-generation H1HR antagonist, decreases visceral hypersensitivity; and there is an ongoing clinical trial to further explore the potential of ebastine in the treatment of IBS. (35) Further, H1HR has been found to be up-regulated in human pediatric biliary atresia, and histamine was also positively correlated with an increase in fibrosis in livers from patients with biliary atresia. (36) The H2HR inhibitor cimetidine has been shown to be a potential treatment for glioblastoma by reducing metastasis, (37) and loxitidine treatment reduces gastric carcinogenesis. (38) In support of our current findings, it has been shown that blocking H1HR inhibits colony growth in pancreatic cancer cells in vitro (39) and that blocking H2HR may inhibit cell proliferation and migration and induce apoptosis in colorectal cancer. (40) Our data found that intracellular signaling mediates histamine-regulated biliary proliferation as shown by our in vitro studies demonstrating that blocking H1HR decreases small cholangiocyte IP 3 levels, whereas H2HR inhibition reduces large cholangiocyte cAMP signaling. These studies are consistent with our previous work showing that histamine alters small and large ductal reactions through independent signaling mechanisms. (16) Further, we found alterations in the Notch/Jagged pathway in our studies using xenograft tumors. Both Notch and Jagged have been demonstrated to play a role in CCA regulation and tumor growth. (41, 42) Wu et al. recently demonstrated that Notch 1, 2, and 3 are important components in CCA proliferation and that inhibition of Notch 2 reduces tumor burden in both CCA and hepatocellular carcinoma. (41, 42) We have found that in HDC knockout mice subjected to 70% partial hepatectomy Notch/Jagged signaling is altered (Francis et al., unpublished observations, 2016) , suggesting that there is a link between histamine and Notch; however, this requires further investigation.
In summary, we have demonstrated in different animal models and human samples that H1HR and H2HR are important regulators of both PSC and CCA progression. Chronic usage of HR inhibitors revealed significant amelioration of pathologies associated with PSC and CCA including decreased (1) biliary damage, (2) hepatic fibrosis, (3) tumor growth, (4) angiogenesis, and (5) EMT switch. With the significant gap in biomarkers and treatments for both PSC and CCA, we aimed to demonstrate that commonly used drugs might offer a benefit to both of these devastating diseases. In addition, elevated MC marker expression and/or increased histamine levels in patients presenting with suspicious symptoms could also represent potential biomarkers to identify disease pathology at an earlier stage. While we recognize that our choice of models does not necessarily mimic human disease exactly, we strongly believe that our data are important in understanding the pathogenesis of both PSC and CCA; and our study implicates both H1HR and H2HR inhibition as promising targets in the quest for a cure for PSC and CCA.
